Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Receivables - Net: 2013-2019

Historic Receivables - Net for Theravance Biopharma (TBPH) over the last 6 years, with Sep 2019 value amounting to $87,000.

  • Theravance Biopharma's Receivables - Net fell 97.12% to $87,000 in Q3 2019 from the same period last year, while for Sep 2019 it was $87,000, marking a year-over-year decrease of 97.12%. This contributed to the annual value of $620,000 for FY2018, which is 72.48% down from last year.
  • Per Theravance Biopharma's latest filing, its Receivables - Net stood at $87,000 for Q3 2019, which was down 21.62% from $111,000 recorded in Q2 2019.
  • Over the past 5 years, Theravance Biopharma's Receivables - Net peaked at $3.4 million during Q2 2018, and registered a low of $87,000 during Q3 2019.
  • Its 3-year average for Receivables - Net is $1.4 million, with a median of $1.3 million in 2017.
  • As far as peak fluctuations go, Theravance Biopharma's Receivables - Net soared by 18,733.33% in 2015, and later crashed by 97.12% in 2019.
  • Theravance Biopharma's Receivables - Net (Quarterly) stood at $1.9 million in 2015, then slumped by 66.39% to $646,000 in 2016, then skyrocketed by 248.76% to $2.3 million in 2017, then plummeted by 72.48% to $620,000 in 2018, then plummeted by 97.12% to $87,000 in 2019.
  • Its last three reported values are $87,000 in Q3 2019, $111,000 for Q2 2019, and $113,000 during Q1 2019.